Cargando…

Rechallenge of immunotherapy beyond progression in patients with extensive-stage small-cell lung cancer

Background: Rechallenge of immunotherapy beyond progression (RIBP) has been demonstrably effective in a variety of cancers. Our study aims to investigate the efficacy of RIBP in small-cell lung cancer (SCLC) patients under real-world conditions. Methods: SCLC patients who experienced progressive dis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Lingling, Liu, Tingting, Liu, Qingyan, Mu, Shuai, Tao, Haitao, Yang, Xuhui, Li, Yao, Xiong, Qi, Wang, Lijie, Hu, Yi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485935/ https://www.ncbi.nlm.nih.gov/pubmed/36147357 http://dx.doi.org/10.3389/fphar.2022.967559

Ejemplares similares

Outcome of immune checkpoint inhibitors in patients with extensive-stage small-cell lung cancer and brain metastases
por: Wang, Chunyu, et al.
Publicado: (2023)

Current Status in Rechallenge of Immunotherapy
por: Hu, Han, et al.
Publicado: (2023)

Rechallenge to Carboplatin in Children with Low Grade Glioma and Carboplatin Hypersensitivity Reactions
por: Ruggiero, Antonio, et al.
Publicado: (2017)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
por: Cui, Qingli, et al.
Publicado: (2022)

Current status of immunotherapy for non-small cell lung cancer
por: Yang, Tao, et al.
Publicado: (2022)

Immunotherapy beyond progression in patients with advanced non-small cell lung cancer
por: Ge, Xiangwei, et al.
Publicado: (2020)

Research progress of interleukin-15 in cancer immunotherapy
por: Cai, Menghan, et al.
Publicado: (2023)

Durvalumab-Induced Demyelinating Lesions in a Patient With Extensive-Stage Small-Cell Lung Cancer: A Case Report
por: Liu, Wenhui, et al.
Publicado: (2022)

Bevacizumab loaded CalliSpheres® bronchial arterial chemoembolization combined with immunotherapy and targeted therapy for advanced lung adenocarcinoma
por: Liu, Haitao, et al.
Publicado: (2023)

Cost-effectiveness analysis of adebrelimab combined with chemotherapy for extensive-stage small cell lung cancer
por: You, Maojin, et al.
Publicado: (2022)

Radiotherapy for extensive-stage small-cell lung cancer in the immunotherapy era
por: Li, Huanhuan, et al.
Publicado: (2023)

TCR Coexpression Signature Predicts Immunotherapy Resistance in NSCLC
por: Wang, Yuntao, et al.
Publicado: (2022)

Progress and prospects of targeted therapy and immunotherapy for urachal carcinoma
por: Zheng, Yang, et al.
Publicado: (2023)

Immunotherapy for extensive stage small cell lung cancer
por: Pacheco, Jose M.
Publicado: (2020)

Immunotherapy in Extensive-Stage Small Cell Lung Cancer
por: El Sayed, Rola, et al.
Publicado: (2021)

Melanoma: BRAFi Rechallenge
por: Kosmidis, Christoforos S., et al.
Publicado: (2023)

Response to Ipilimumab/Nivolumab Rechallenge and BRAF Inhibitor/MEK Inhibitor Rechallenge in a Patient with Advanced Metastatic Melanoma Previously Treated with BRAF Targeted Therapy and Immunotherapy
por: Myrdal, Caitlyn N., et al.
Publicado: (2020)

Immunotherapies for advanced hepatocellular carcinoma
por: Sun, Li-Yang, et al.
Publicado: (2023)

Case report: Rechallenge with EGFR–TKIs after immunotherapy in EGFR–mutated non–small cell lung cancer with leptomeningeal metastasis
por: Qian, Chunfa, et al.
Publicado: (2022)

TAAR1 in Addiction: Looking Beyond the Tip of the Iceberg
por: Liu, Jian-Feng, et al.
Publicado: (2018)

Advances in immunotherapy modalities for atherosclerosis
por: Meng, Qingwen, et al.
Publicado: (2023)

The Application of and Strategy for Gold Nanoparticles in Cancer Immunotherapy
por: He, Jia-shuai, et al.
Publicado: (2021)

Association between immune-related adverse events and immunotherapy efficacy in non-small-cell lung cancer: a meta-analysis
por: Lin, Li, et al.
Publicado: (2023)

Immunotherapy Resumption/Rechallenge in Melanoma Patients after Toxicity: Do We Have Another Chance?
por: España Fernandez, Sofia, et al.
Publicado: (2023)

Plasticity of lineage switch in B-ALL allows for successful rechallenge with CD19-directed immunotherapy
por: Lee, Brittany M., et al.
Publicado: (2023)

Immunotherapy Summary for Cytokine Storm in COVID-19
por: Li, Yaqun, et al.
Publicado: (2021)

Chronic inflammation, cancer development and immunotherapy
por: Wen, Yalei, et al.
Publicado: (2022)

Significant metabolic alterations in non-small cell lung cancer patients by epidermal growth factor receptor-targeted therapy and PD-1/PD-L1 immunotherapy
por: Yan, Chen, et al.
Publicado: (2022)

Adebrelimab plus chemotherapy vs. chemotherapy for treatment of extensive-stage small-cell lung cancer from the US and Chinese healthcare sector perspectives: a cost-effectiveness analysis to inform drug pricing
por: Gan, Yena, et al.
Publicado: (2023)

Drug resistance mechanism and reversal strategy in lung cancer immunotherapy
por: Xu, Yishi, et al.
Publicado: (2023)

Immunotherapy for Stage III NSCLC: Durvalumab and Beyond
por: Fitzpatrick, Orla, et al.
Publicado: (2021)

Cost-Effectiveness of Frontline Treatment for Advanced Renal Cell Carcinoma in the Era of Immunotherapies
por: Li, SiNi, et al.
Publicado: (2021)

Doubling the Dose of Bevacizumab Beyond Progression in Metastatic Colorectal Cancer–the Experience of a Tertiary Cancer Center
por: Căinap, Călin, et al.
Publicado: (2021)

Integrating machine learning to construct aberrant alternative splicing event related classifiers to predict prognosis and immunotherapy response in patients with hepatocellular carcinoma
por: Liu, Wangrui, et al.
Publicado: (2022)

Ganoderma: A Cancer Immunotherapy Review
por: Cao, Yu, et al.
Publicado: (2018)

Rechallenge of lamotrigine after development of rash
por: Houser, Jennifer, et al.
Publicado: (2018)

Lithium rechallenge after renal transplant
por: Beasley, Anna K., et al.
Publicado: (2018)

5-Fluorouracil Rechallenge After Cardiotoxicity
por: Desai, Aakash, et al.
Publicado: (2020)

Natural Polysaccharides and Their Derivates: A Promising Natural Adjuvant for Tumor Immunotherapy
por: Li, Ye, et al.
Publicado: (2021)

Increased plasma renin by vasodilators promotes the progression of abdominal aortic aneurysm
por: Liu, Yu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_63odrl8hmb6kfvh7tepsaghsue